Double-blind Studies required by the FDA to es. Tablish the effectiveness and safety of antiamoebic compounds in the treatment of rheumatoid arthritis, will be conducted at the bowman-gray School of Medicine. The drug that has been selected for the test is Clotrimazole, an anti-protozoal compound from the Imidazole family.
Double-blind Studies required by the FDA to es. Tablish the effectiveness and safety of antiamoebic compounds in the treatment of rheumatoid arthritis, will be conducted at the bowman-gray School of Medicine. The drug that has been selected for the test is Clotrimazole, an anti-protozoal compound from the Imidazole family.
Double-blind Studies required by the FDA to es. Tablish the effectiveness and safety of antiamoebic compounds in the treatment of rheumatoid arthritis, will be conducted at the bowman-gray School of Medicine. The drug that has been selected for the test is Clotrimazole, an anti-protozoal compound from the Imidazole family.